REMARKS

Reconsideration of this application is requested in view of the amendment to the specification and the new set of claims and the remarks presented herein.

A new brief description of the drawings has been inserted in the specification taking account of the wording appearing in the examples to better and more precisely define the subject of the drawings 10 to 20. These new definitions with proposed corrections are underlined for approving by the examiner. They do not contain any new matter.

Claims 4 to 33 have cancelled and their drafting have been reviewed in order to obviate any objection of unclarity or new matter added. New claims 34 to 49 should overcome any objection.

Namely the objection against claims 32 and 33 relating to the presence of an integer q + 1 has not any reason since this integer appears in the specification on page 5 and page 8 last line. Position ω is clearly defined as being the terminal position of the diamino alcohol or of the diamino acid of formula $HN\text{-}(CH_2)n\text{-}CH(NH_2)\ (CH_2)q+1COOH$

The "amino functional group in position (q+1)" means that this group is not terminal and stands in the internal part of this chain such as defined in the formula :

$$\underline{{}_2HN}\text{-}(CH_2)\,p - \underset{\underset{\underline{NH\,R_2}}{\Downarrow}}{\overset{|}{CH}}\text{-}(CH_2)_{q+1}COOH$$

ω amino group

Q+ 1 amino group

In this manner such substituents are clearly defined.

In view of the amendments set forth in the specification and in the claims and of the clarification in the drafting of the claims, it is believed that the claims clearly point out Applicant's patentable and valuable contribution and favourably reconsideration of the application is requested.

Respectfully submitted,
Muserlian, Lucas and Mercanti

Charles A. Muserlian, 19,683
Attorney for Applicant(s)
Tel. # (212) 661-8000

Enclosure: Return Receipt Postcard

Our Ref: GEI-084

"EXPRESS MAIL" Mailing Label Number EV 530583079 US

Date of Deposit September 2, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" Service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Charles A. Muserlian, 19,683

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph of murine bone marrow stem cell proliferation and Fig. 2 is a graph of NO production in murine macrophage cells;

Figs. 3, 4 and 5 are graphs of Dextran-FITC conjugate take up by human dendritic cells differentiated from monocytes isolated from peripheral blood;

Fig 6 is a graph of CD40 surface marker expression from human dendritic cells;

Figs. 7, 8 and 9 are graphs of CD86, CD83 and CD80 surface marker expression, respectively, from human dendritic cells;

Fig 10 are graphs of OM 294 MP and OM 294 DP effects of TNF-α production by predendritic cells at DC-6 stage

Fig 11 are graphs of OM 294 MP and OM 294 DP on IL-12 p 70 production by predentritic cells at DC – 6 stage

Fig 12 are graphs of the effect of OM 294 MP on IL-12 p 70 production in the supernatant fluid of monocytes

Figs. 13, 14 and 15 are graphs of ELISA 2, 3 and 4-weeks after the first, second and third immunization of mice with the synthetic peptide PbCS His-6 242-310 amino acid sequence of Plasmodium berghei circumsporozoite

Fig. 16 is a graph of antibody titer before and after immunization of mice with the synthetic peptide PbCS His-6 242-310 amino acid sequence of Plasmodium berghei circumsporozoite

Figs. 17 to 20 are graphs of ELISPOT IFN-γ producing lymphocytes after immunization of mice with the synthetic peptide PbCS His-6 242-310 amino acid sequence of Plasmodium bergei circum sporozoite

Fig 21 is an electropherogram

Figs. 22 to 29 are graphs of specific mouse antibodies directed to specific antigens;

Figs. 30(a) and 30(b) are graphs of anti-gp63 immune response and Figs. 31(a) and 31(b) are graphs of lymph node lymphocyte response;

Figs. 32(a) and 32(b) are graphs of anti-LmCPb immune response;

Fig. 33 to 38 are schemes outlining the synthetic processes of the invention

Fig. 39 to 41 are Mass spectra of the compounds of the invention

Fig. 42 and 43 are ^{1}H-NMR spectra of the compounds of the invention

Fig. 44 and 45 are ^{13}C- NMR spectra of the compounds of the invention

Fig. 46 and 47 are ^{31}P- NMR spectra of the compounds of the invention